- Home
- CELZ vs MBIO Comparison
CELZ vs MBIO Comparison
Compare CELZ & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELZ | MBIO |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 6.2M |
| IPO Year | 2008 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CELZ | MBIO |
|---|---|---|
| Price | $1.91 | $0.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.5K | ★ 31.5K |
| Earning Date | 05-08-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.08 | ★ 98.99 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $0.53 |
| 52 Week High | $6.25 | $7.00 |
Technical Indicators
Market Signals| Indicator | CELZ | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.07 | 29.24 |
| Support Level | $1.72 | $0.53 |
| Resistance Level | $2.30 | $1.00 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 100.00 | 3.16 |
Price Performance
Historical ComparisonAbout CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.